Lion TCR, a Singapore-headquartered clinical-stage biotech company, reported significantly higher losses for the year ended December 31, 2021, on zero revenues as it continued to work on clinical trials of its chronic Hepatitis B treatments.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
